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Abstract
Background: Fatigue is a common and sometimes debilitating phenomenon in primary Sjögren’s syndrome (pSS)
and other chronic inflammatory diseases. We aimed to investigate how IL-1 β-related molecules and the
neuropeptide hypocretin-1 (Hcrt1), a regulator of wakefulness, influence fatigue.
Methods: Hcrt1 was measured by radioimmunoassay (RIA) in cerebrospinal fluid (CSF) from 49 patients with pSS.
Interleukin-1 receptor antagonist (IL-1Ra), IL-1 receptor type 2 (IL-1RII), IL-6, and S100B protein were measured by
enzyme-linked immunosorbent assay (ELISA). Fatigue was rated by the fatigue visual analog scale (fVAS).
Results: Simple univariate regression and multiple regression analyses with fatigue as a dependent variable
revealed that depression, pain, and the biochemical variable IL-1Ra had a significant association with fatigue. In
PCA, two significant components were revealed. The first component (PC1) was dominated by variables related to
IL-1β activity (IL-1Ra, IL-1RII, and S100B). PC2 showed a negative association between IL-6 and Hcrt1. fVAS was then
introduced as an additional variable. This new model demonstrated that fatigue had a higher association with the
IL-1β-related PC1 than to PC2. Additionally, a third component (PC3) became significant between low Hcrt1
concentrations and fVAS scores.
Conclusions: The main findings of this study indicate a functional network in which several IL-1β-related molecules
in CSF influence fatigue in addition to the classical clinical factors of depression and pain. The neuropeptide Hcrt1
seems to participate in fatigue generation, but likely not through the IL-1 pathway.
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Background
Fatigue can be defined as “an overwhelming sense of
tiredness, lack of energy, and feeling of exhaustion” [1]
and is a common phenomenon in infections, chronic
inflammatory diseases, cancer, and neurodegeneration.
Fatigue has a substantial impact on patients’ lives, is
sometimes debilitating, and is a major reason for using
sick leave. It remains unclear whether there are different
dimensions of fatigue, such as peripheral (muscle) and
central (mental) fatigue, or whether fatigue is a unidi-
mensional phenomenon that influences different aspects
of human life.
While the underlying mechanisms are not completely
understood, several studies have shown that pain and de-
pression are factors that exert a heavy and consistent in-
fluence on the severity of fatigue [2, 3]. Most researchers
regard fatigue as a biological and cerebral phenomenon,
and increasing evidence points to a genetic and molecular
basis for the generation and regulation of fatigue [4, 5].
A conceptual model for understanding fatigue is the
sickness behavior phenomenon in animals [6, 7]. “Sickness
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behavior” is observed during infection and inflammation
and is characterized by sleepiness, depressive mood, social
withdrawal, and loss of grooming, thirst, appetite, and ini-
tiative [8]. Sickness behavior can be considered as a
survival-enhancing strategy and is highly conserved during
evolution [9]. Fatigue constitutes a substantial part of this
behavior.
Several animal studies have explored the pathways in-
volved in sickness behavior and demonstrated the funda-
mental role of interleukin (IL)-1β signaling to the brain for
this complex and automated response [6]. In conditions
with infection and/or tissue injury, activation of innate im-
munity cells such as macrophages will rapidly lead to in-
creased production of IL-1β. This activates other immune
cells to destroy and eliminate the pathogen or the endogen-
ous danger molecules. In the periphery, IL-1β signals
through binding the IL-1 receptor type 1 (IL-1RI) and the
IL-1R accessory protein (IL-1RAcP) [7]. Activation of this
signaling complex gives rise to the canonical downstream
IL-1 responses (NF-κB and MAPKs) with increased inflam-
mation and immune cell activation. Downregulation of
IL-1 induced receptor activation is conducted by the IL-1
receptor type II (IL-1RII), which functions as a decoy recep-
tor and does not signal, and by the natural IL-1 receptor
antagonist (IL-1Ra), which binds to the IL-1RI and prevents
activation [10]. Without these limiting steps, IL-1-driven in-
flammation can run rampant.
IL-1β passes through the blood-brain barrier (BBB)
and reaches neuronal cells in the brain by both passive
and active transport systems and can even be produced
intrathecally [11]. Once in the brain, IL-1β binds to a
subtype of the IL-1 receptor and to a brain isoform of
the accessory protein, the IL-1RaAcPb [12]. Thus, while
IL-1β in the periphery is a strong inducer of innate
immunity-based inflammation, IL-1β directly modulates
synaptic transmission through neuronal potassium and
calcium influx (without inflammation) in the brain [12,
13] and induces sickness behavior. IL-1Ra is a robust
biomarker in CSF and is in equilibrium with IL-1β in
chronic conditions. High levels of IL-1Ra in CSF there-
fore are thought to reflect high IL-1β levels.
In humans, increased activation of IL-1 in the brain is
observed in chronic inflammatory and autoimmune con-
ditions [14, 15], and treatment with IL-1 blocking agents
alleviates fatigue [16–18]. In primary Sjögren’s syndrome
(pSS), a chronic autoimmune disease clinically character-
ized by inflammation of the exocrine glands, fatigue is a
dominant feature [19]. No consistently effective treat-
ments are currently available, and pSS can be considered
as an ideal disease to investigate fatigue mechanisms as
gene expression and molecular pathways at large are un-
disturbed by immunosuppressive or cytotoxic drug treat-
ment. To further explore models for fatigue regulation, we
therefore performed measurements of selected molecules
in cerebrospinal fluid (CSF) that could influence Il-1β ac-
tivity (IL-1Ra, IL-1RII, IL-6, and S100B).
Animal studies show that lipopolysaccharide (LPS)-in-
duced sickness behavior also is accompanied by reduced
c-fos activity of lateral hypothalamic neurons that pro-
duce hypocretin-1 (Hcrt1) and also a reduction of Hrct1
levels in CSF [6, 20]. Since Hcrt1 is known as the main
regulator of sleep and wakefulness, we also hypothesize
that this neuropeptide could be another molecular regu-
lator of fatigue.
Methods
This hypothesis-generating study was designed to ex-
plore associations between the CSF concentrations of se-
lected molecules and fatigue in a population of patients
with pSS at a single institution.
All patients with systemic autoimmune diseases in the
Southern part of Rogaland County are allocated to Stavan-
ger University Hospital. We reviewed medical records and
identified 99 patients that fulfilled the
American-European Consensus Group (AECG) criteria
for pSS [21]. None of the patients were on biological drug
treatment. Exclusion criteria were past head and neck ra-
diation treatment, hepatitis C infection, acquired im-
munodeficiency syndrome (AIDS), pre-existing
lymphoma, sarcoidosis, graft versus host disease, and use
of anticholinergic drugs [21]. Seventy-two patients con-
sented to participate in the study and subjected to a 2-day
stay in the hospital for research purposes only. The pa-
tients in the near population-based cohort were on no
biological drug treatment. Fifty-five of the 72 patients
(76%) consented to lumbar puncture. One of the 55 pa-
tients was later excluded due to a brain tumor revealed by
MRI, three because of blood contamination of the CSF,
and another two because of inadequate sample volumes.
Thus, CSF samples from 49 out of the 72 pSS patients
(68%) were available for study, 41 women (84%) and 8
men (16%).
Blood was drawn in the morning between 08.00 and
09.00 a.m, and clinical examinations and patient-reported
outcome measures completed afterwards. Lumbar punc-
ture was performed between 01:00 and 02:00 pm; samples
were collected in cooled glass tubes and immediately
placed on ice until centrifugation at 3000 g for 10 min at
4 °C. The supernatants were distributed in 200 μL aliquots
and stored at − 70 °C until analysis. CSF samples from
three patients were excluded because of blood contamin-
ation, and another two because of inadequate sample vol-
umes. Thus, CSF samples from 50 pSS patients were
available for study. In addition to clinical variables given
in Table 1, four patients (8 %) had a BMI ≥ 30, 18 patients
(36 %) were on antimalarial drugs, and the median dur-
ation of education was 12.3 years (range 7–20 years).
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Fatigue was assessed by the fatigue visual analog scale
(fVAS), which is a generic and unidimensional fatigue in-
strument that has been widely used to measure fatigue
in patients with various conditions [22]. It consists of a
10- mm horizontal line with vertical anchoring lines.
The description at the left end (0 mm) is “no fatigue,”
and the description at the right end (100 mm) is “fatigue
as bad as it can be.” The subjects are asked to draw a
vertical line at the point corresponding to their experi-
ence of fatigue the last week, and the distance from the
left anchor is measured, yielding a numerical score for
fatigue (Additional file 1: Figure S1).
Mood was assessed by the Beck Depression Inventory
(BDI) [23]. A BDI score of < 13 is normally regarded as no
depression; a score of 13–19 represents mild depression
and a score of >19 reflects moderate-to-severe depression.
Pain was assessed by the pain subscale of the Medical
Outcome Survey (MOS) short form-36 (SF-36) question-
naire and transformed as recommended [24].
For regression analysis and principal component ana-
lysis (PCA), the transformed pain scale was inverted by
subtracting the transformed score from 100. This was
performed to orient the pain scale in the same direction
as scales for other variables included in the analyses.
IL-1Ra and IL-6 were analyzed on a Luminex100 in-
strument (Luminex Corp., Austin, TX). IL-1Ra was mea-
sured using a Fluorokine MAP human IL-1Ra kit (R&D
Systems, Minneapolis, MN) and a Fluorokine MAP hu-
man base kit (R&D Systems) according to manufac-
turer’s protocols. Intra-assay CV% was 2.8–4.4, and
inter-assay CV% was 6.6–10.9. IL-6 was measured using
a human IL-6 ultrasensitive AB bead kit with the human
extracellular buffer kit (Biosource, Invitrogen Corp.,
Carlsbad, CA). Intra-assay CV% was 7.59 and inter-assay
CV% was 9.9. For both IL-1Ra and IL-6, acquired data
were studied using the StarStation software v2.3 (Ap-
plied Cytometry, Sheffield, UK). In the IL-6 assay, nine
samples had values below the standard curve and were
given the value of the detection limit (1.0 pg/mL) divided
by the square root of 2.
Because IL-1β is difficult to measure in CSF due to
low concentrations, these results were not included.
S100B and IL-1RII concentrations were measured by
sandwich ELISA kits according to the manufacturer’s
protocol (S100B: Abnova, Taipei City, Taiwan; IL-1RII:
R&D Systems, Minneapolis, MN). ELISA plates were
read on a Multiskan Ascent microplate reader (Thermo
Scientific, Waltham, MA). For S100B ELISA kits, the
intra-assay and inter-assay CV% were 1.9–2.1 and 4.7–
7.1, respectively. For IL-1RII, the intra-assay CV% was
2.0–3.4 and the inter-assay CV% was 3.9–5.9.
The concentration of Hcrt1 in CSF was measured by
I125 radioimmunoassay (RIA) (Phoenix Pharmaceuticals,
Burlingame, CA, USA) per manufacturer’s protocol.
Samples were measured in duplicate and assay tubes
were counted on a RIASTAR gamma counter (Perkin
Elmer, USA). Briefly, 100 μL of standard dilution, assay
controls, and CSF samples were added to assay tubes to-
gether with 100 μL primary antibody and incubated for
20 h at 4 °C before adding 100 μL of 125I-peptide (tracer
solution) and a new incubation for 20 h at 4 °C. After the
second incubation, 100 μL of goat anti-rabbit serum and
100 μL normal goat serum was added. Following incuba-
tion for 90 min at room temperature, the assay tubes
were centrifuged at 300 rpm for 20min at 4 °C and incu-
bated for 90 min at room temperature. The supernatant
was aspirated before counts per million was counted
from the remaining pellet. The average CSF Hcrt1 con-
centration was 239.3 ± 26.8 pg/mL. Intra-assay variation
was 9.9% based on a sample assayed as ten individual
samples.
Statistics
Some clinical variables were not normally distributed,
and all continuous data are therefore reported as me-
dians and ranges. Categorical data are reported as counts
and percentages. Simple univariate linear regression was
first used to examine associations between fatigue and
each of the potential influential factors, BDI, pain scores,
IL-1Ra, IL-1RII, IL-6, S100B, and Hcrt1. Thereafter, a
multiple regression analysis with forward and backward
selection was performed to investigate the mutual effect
of these factors on fatigue. Variables selection in the final
model was based on variables with a significant contri-
bution (p < 0.05) and the lowest Akaike’s information cri-
terion (AIC) value. AIC evaluates the multiple regression
model by favorizing higher explained variance and pen-
alizing the number of variables in the model. Thus, the
model with the lowest AIC was selected.
To further explore and visualize the complex inter-
action of multiple clinical and laboratory variables on fa-
tigue, we applied principal component analysis (PCA).
Table 1 Selected clinical variables in the 49 pSS patients
Variables
Females (%)/males (%) 41 (84)/8 (16)
Age, years, median [range] 56.1 [34.2–78.2]
Duration, years, median [range] 5.0 [0.4–16.0]
fVAS scores, median [range] 64 [3.0–93.0]
BDI scores, median [range] 9.0 [0.0–38.0]
Pain scores*, median [range] 49.0 [0.0–90.0]
Presence of anti-SSA/SSB antibodies (%) 38 (78)
CRP (mg/L) [range] 1.5 [0.0–9.0]
Abbreviations: fVAS fatigue visual analog scale, BDI Beck Depression Inventory,
SSA/SSB Sjögren’s syndrome-related antigen A (Ro) and B (La), CRP
C-reactive protein
*SF-36 pain scores are reported according to the transformed scale with high
scores indicating high bodily pain and low scores indicating lower bodily pain
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Centering and standardizing of the data were performed
before analysis to avoid effects due to differences in
units of the variables. The components retained in PCA
were those with eigenvalues > 1. Score distance plots
and orthogonal distance plots were used to detect pos-
sible outliers in PCA. Samples outside a critical bound-
ary, the 97.5 % quantile in these plots, were declared as
outliers.
All analyses were performed in R version 3.3.3 using
RStudio version 1.0.144. PCA was performed using the
R package FactoMinerR.
Results
Patient characteristics are summarized in Table 1. There
was no significant difference in routine hematological or
biochemical variables between patients with high or low
fatigue. Diagnostic evaluation of the PCA revealed that
one sample was classified as an orthogonal outlier. This
sample was removed and PCA was thus performed on
48 samples.
The clinical variables of depression and pain and the
biochemical variable IL-1Ra were significantly associated
with fatigue in simple univariate linear regression, while
no significant associations were observed for Il-1RII,
IL-6, S100B, or Hcrt1 (Table 2). In multiple linear re-
gression analysis with fVAS as the dependent variable,
both forward and backward stepwise selection resulted
in a model with depression, pain, and IL-1Ra as signifi-
cant independent variables (R2 = 0.37; p < 0.001, Table 3).
To obtain an unsupervised impression of the complex
molecular interactions, we first performed PCA on a
model containing only the biochemical variables. Data
from the biochemical variables were centered and scaled
before analysis and PCA was performed on the correl-
ation matrix. Two components demonstrated eigen-
values > 1 in a Scree plot and were retained (Additional
file 2: Figure S2a). These two components explained
62.77 % of the variation in the dataset.
In the PCA bi-plot (Fig. 1a, b), patients are illustrated
as dots and the variables as arrows. The length of an
arrow is a function of its magnitude, and variables with
longer arrows in the direction of a principal component
will contribute most to the generation of this specific
component.
The first component (PC1) explained most of the vari-
ance (35.66 %) (Fig. 1a), and the variable with the high-
est correlation with the first dimension was S100B
(0.79), followed by IL-1Ra (0.78) and IL-1RII (0.68). The
fatigue-related variable IL-1Ra revealed in simple and
multiple regression analyses was thus highly correlated
with S100B and IL-1RII. These results indicate that the
first dimension was dominated by variables related to
IL-1β activity, the IL-1 dimension.
The second component (PC2)—the Hcrt1/IL-6 dimen-
sion—explained 27.11 % of the variance in the dataset
(Fig. 1a). Hcrt1 and IL-6 were the variables with the
highest correlation, 0.82 and 0.78, respectively. The
negative correlation of Hcrt1 in the second dimension
indicates that individuals with low CSF concentrations
of Hcrt1 also had high IL-6 concentrations.
In a second PCA model (Fig. 1b), fVAS scores were in-
troduced as an additional variable to explore how fatigue
contributed to the data cloud together with the bio-
chemical components. In this model, PCA resulted in
three components with eigenvalues > 1 explaining 71.63
% of the variance in the dataset (Additional file 2: Figure
S2b). IL-1Ra showed the highest correlation (0.79) with
PC1, followed by S100B (0.76), IL-1RII (0.63), and fVAS
(0.48). IL-6 had the highest correlation (0.84) with PC2,
followed by a negative Hcrt1 correlation (− 0.70). In the
third component (data not shown), the variables with
the highest correlation were fatigue (− 0.76) and Hcrt1
(0.58).
Adding fatigue-scores to the PCA resulted in a new
data cloud in which the composition of the two first
components was similar to the components in the PCA
model without fatigue (Fig. 1a). Thus, rather than gener-
ating new dimensions or changing the composition of
the components in the data cloud, fatigue showed a
Table 2 Associations (simple regression analysis) between
fatigue (fVAS scores) and selected variables
Independent variables Estimate Std. error R2 P
Depression (BDI) scores 1.42 0.42 0.20 0.001
Pain (SF-36) scores* 0.48 0.13 0.23 < 0.001
IL-1Ra 0.52 0.24 0.09 0.04
IL-1RII 0.13 0.16 0.01 0.41
IL-6 − 3.47 2.43 0.04 0.16
S100B 0.05 0.04 0.03 0.22
Hcrt1 − 0.04 0.14 0.002 0.76
Abbreviations: BDI Beck Depression Inventory, SF-36 36-item short form survey
instrument, IL-1Ra interleukin 1 receptor antagonist, IL-1RII interleukin 1
receptor type 2, IL-6 interleukin 6, S100B S100 calcium binding-protein B, Hcrt1
hypocretin 1
*SF-36 pain scores are reported according to the transformed scale with high
scores indicating high bodily pain and low scores indicating low bodily pain
Table 3 Multiple regression model of fatigue (fVAS scores) and
selected variables
Variables Estimate Std. error P
Depression (BDI) scores 0.97 0.40 0.019
Pain (SF-36) scores* 0.38 0.13 0.004
IL-1Ra 0.54 0.19 0.009
Statistics for the final model: adjusted R2 0.37, P value < 0.001
Abbreviations: BDI Beck Depression Inventory, SF-36 36-item short form survey
instrument, IL-1Ra interleukin 1 receptor antagonist
*SF-36 pain scores are reported according to the transformed scale with high
scores indicating high bodily pain and low scores indicating low bodily pain
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moderate association with variables on PC1 and a strong
negative association with Hcrt1 on PC3.
Discussion
The main findings in this study indicate a complex func-
tional network in which clinical phenomena (pain and
depression) together with several IL-1-related molecules
in CSF influence fatigue in the context of sickness
behavior. In addition, a role for the neuropeptide Hcrt1
as a fatigue-inducing molecule emerges.
Regarding molecules that relate to the IL-1 network, it
is difficult to note the specific actions and relative im-
portance of different molecules, but a common denom-
inator seems to be a final IL-1β signaling of fatigue in
the brain. The influence of the other biomarkers mea-
sured in CSF “disappear” in the complex biological
Fig. 1 a PCA of the biochemical variables only. b PCA of the biochemical variables and fatigue variable (fVAS). Bi-plot shows scores of the
individuals and variable correlations for PC1 and PC2. Individual scores are illustrated by dots. Arrows illustrate the correlations of the variables to
the components. Longer arrows mean higher correlation and arrows close to a component has a higher contribution in the generation of
the component
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network interactions and only become evident in more
advanced statistical models. In addition, the neuropep-
tide Hrct1—the main regulator of sleep and wakefulness—
could represent a parallel, alternative, or redundant fatigue
mechanism operative in inflammatory conditions and pos-
sibly driven by IL-6/TNF-α modulation of Hcrt1 (Fig. 2).
As shown in a number of previous studies, the clinical
factors of pain and depression have a strong influence
on fatigue. Whether these factors modulate the fatigue
experience on a more psychological basis, whether pain
generates fatigue through neuropeptide signaling, or if
fatigue and depression are both signaled by IL-1 is not
understood. Both animal and human studies have docu-
mented IL-1 signaling as one of the mechanisms under-
lying depression [25, 26]. Depression is also an important
component of the sickness behavior response, in which fa-
tigue is such a dominant phenomenon. The close associ-
ation between fatigue and depression observed in so many
studies may therefore have a biological explanation.
Pain is also a well-known associate of fatigue; many
different explanations have been proposed to explain this
constellation. Patients with chronic pain syndromes such
as fibromyalgia consistently report fatigue. Recently, we
revealed that fatigue in patients with pSS was associated
with variance in a gene coding for an opioid transporter
protein in which the more common allele had more se-
vere fatigue [27]. One could therefore hypothesize that
pain in an evolutionary perspective is a “danger signal”
that induces sickness behavior. Regarding depression, pain
and fatigue may therefore also have a biological basis.
In regard to biochemical factors, animal and human
studies in acute and chronic inflammation show that IL-1
signaling is crucial for the sickness behavior response, in
which fatigue is a major element. Most human studies
using peripheral blood have not been able to demonstrate
an influence of any cytokine on fatigue. Peripherally pro-
duced cytokines and other molecules have to cross the
blood-brain barrier to act on the brain, where fatigue is
generated. However, cytokines act in complex networks
and the effect of one single cytokine upon a dependent
factor such as fatigue can be difficult to evaluate. In the
CSF, this can be even more problematic, as, for example,
IL-1β appears in very low concentrations. Traditional stat-
istical approaches may not detect effects unless they are
extremely dominating. To decipher complex interactions
in systems-biology research, it may therefore be of benefit
to use alternative statistical approaches such as PCA. In
this study, the initial regression analyses only found
IL-1Ra of the biochemical factors to be a significant con-
tributor, while in the PCA analyses, a logical pattern of
molecular interactions for fatigue regulation became evi-
dent. A caveat in the deduction of processes that drive
PCA dimensions is that other unmeasured covariates
could be operative. It is for example known that IL-6 can
Fig. 2 Hypothetical model for fatigue. Danger signals activate astroglia to produce and release S100B that bind to TLR4 and RAGE receptors on
microglia. Activated microglia produce IL-1β that bind specific receptors (IL-1R1/IL-1RAcPb) on neurons and induce sickness behavior. There are
no specific receptors for IL-6 that can modulate neurons in the same manner as for IL-1β, but higher levels of IL-6 may through stimulation of
TNFα synthesis reduce the amount of Hcrt-1 in neurons. Low levels of Hcrt-1 can lead to or modulate fatigue through unknown pathways
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elicit an IL-1Ra response independent of IL-1β secretion
[28]. Nevertheless, these observations expand the know-
ledge of how fatigue can be generated and allows a more
comprehensive understanding of the biological basis
of fatigue in inflammatory and possibly also in
non-inflammatory conditions.
In the proposed model for fatigue (Fig. 2), IL-1β can ei-
ther originate from the periphery after passing the
blood-brain barrier or be produced intrathecally by acti-
vated microglia. In the latter case, protein S100B secreted
by activated astrocytes can signal through RAGE and TLR4
on microglia and lead to IL-1β production [29, 30]. Astro-
cytes are the most numerous cells in the mammalian brain
and have a wide range of functions. They comprise an im-
portant component of the blood-brain barrier and contact
endothelial cells with their end-feet. The importance of as-
trocytes in innate and adaptive immune responses in the
brain has become more clear in recent years [31]. Activa-
tion of astrocytes and microglia may therefore in states of
inflammation be the initial step in fatigue generation and
could possibly also represent a mechanism by which states
with cellular stress or “danger” such as degenerative dis-
eases and cancer induce fatigue through microglia IL-1β
production.
Sickness behavior is regarded as an important survival
factor in evolution, and it is therefore plausible that
pathways other than IL-1-driven mechanisms may have
developed and can be operative in non-inflammatory
and malignant conditions. In this context, Hcrt1 is an
interesting candidate. Lack of Hcrt1 is the cause of nar-
colepsy type 1 [32, 33], and chronic fatigue is prevalent
and strong in this condition [34]. It is known that low
levels of Hcrt1 also lead to reduced appetite [35]. Low
levels of Hcrt1 in CSF may therefore influence both ap-
petite and fatigue, two prominent components of the
sickness behavior response.
Studies on Hrct1 and fatigue are rare. There are several
case reports of multiple sclerosis patients with hypothal-
amic lesions with low Hrct1 in CSF and with accompanying
hypersomnia or fatigue, but cohort studies are conflicting;
for a review, see Burfeind et al. [36]. In cancer, fatigue is
common and worsens during cytotoxic treatment. One
study in rodents showed that suppression of activity in the
hypothalamic Hcrt-producing neurons and low Hcrt1 con-
centrations in CSF occurred during cytotoxic treatment
and had a causal role in chemically induced fatigue [37].
When administered to humans, hypocretin receptor antag-
onists typically are associated with the side effects of sleepi-
ness and fatigue, indicating that when hypocretin receptors
are blocked, subjects experience fatigue [38].
In our study, high inflammatory activity in CSF (IL-6
high) was accompanied by low Hcrt1 (Fig. 1a, b). IL-6
that can be produced by a variety of cells induces pro-
duction of TNF-α, which again is able to downregulate
mRNA prepro-hypocretin, the precursor of Hrct1 [39].
Unfortunately, we did not measure TNF-α in this study
and can therefore only speculate that in states of infec-
tion, damage or immunological danger, IL-6 leads to low
levels of Hcrt1 and induces fatigue via a
TNF-α-dependent mechanism. Although the target re-
ceptor or cells are unknown, this pathway may represent
an alternative fatigue mechanism besides IL-1 signaling.
Limitations of this study include the small number of
patients in the cohort and the low number of variables
included in the analysis. A larger cohort would provide
higher statistical power for both univariate and multiple
regression analyses and the PCA. TNF-α analyses in CSF
would have provided a greater impact on the Hcrt1 hy-
pothesis for fatigue signaling. Measures of IL-β would
have provided a better understanding of its role in the
proposed network. Due to the very low CSF concentra-
tions, robust data is difficult to obtain. However, since
IL-1Ra downregulates IL-1β activity, it can be consid-
ered as a surrogate marker for IL-1β. Strong arguments
in support of this is a study of patients with aseptic
meningitis revealing CSF IL-1Ra levels approximately
2,000 times the level of IL-1β. IL-1Ra levels peaked
about 12 h after IL-1β levels [40]. Another study in ani-
mals found that hypothalamic IL-1β mRNA peaked 1 h
after intraperitoneal LPS injections, whereas IL-1Ra
mRNA peaked after 3–6 h [41].
The study’s strengths include a well-characterized pa-
tient cohort not under drug treatment that potentially
could affect the analysis and the use of CSF for analysis
instead of peripheral blood.
These results need to be validated in future studies, and
especially it would be interesting to further explore the
role for Hrct1 signaling of fatigue and also to apply more
sensitive and accurate assays for IL-1β measures in CSF.
Conclusion
The main findings of this study indicate a functional net-
work in which several IL-1β-related molecules in CSF
influence fatigue in addition to the clinical factors of de-
pression and pain. The neuropeptide Hcrt1 seems to
participate in fatigue signaling, but probably not through
the IL-1 pathway.
Additional files
Additional file 1: Figure S1. The visual analog scale (fVAS) used for
scoring of fatigue. (DOC 25 kb)
Additional file 2: Figure S2. a) Scree-plot of the eigenvalues of compo-
nents 1–5 from PCA model with biochemical variables only. Components 1
and 2 had eigenvalues > 1 and were retained in the analysis. b) Scree-plot of
the eigenvalues of components 1–6 from the PCA model with biochemical
variables and fatigue (fVAS). The first three components had eigenvalues > 1
and were retained in the analysis. (TIFF 533 kb)
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